Safely Guiding the Immune System to Fight Disease
Eradivir makes small molecules that target diseased cells and viruses flagging them for clearance by the immune system
Our Vision
With a toolkit of these antibody recruiting small molecules, we are advancing a pipeline of candidates to treat multiple diseases, from viral infections to cancer.
Rethinking Influenza Treatment: Beyond Conventional Antivirals
Seasonal influenza continues to be a major global health challenge, resulting in billions of infections and hundreds of thousands of deaths every year. Current standard-of-care treatments require early administration, highlighting the need for treatment options for patients who seek care after symptoms have progressed.
We are developing EV25 to address this treatment gap. EV25 is a small molecule designed to bind to infected cells and virions and recruit existing circulating antibodies, which instigates rapid and targeted immune clearance. Our approach creates the potential for a new therapeutic option to treat both early- and late-stage influenza infections.
Eradivir has assembled a team of seasoned industry leaders, world class scientists and expert advisors.
